Premium
Patient satisfaction with treatments for moderate‐to‐severe plaque psoriasis in clinical practice
Author(s) -
Callis Duffin K.,
Yeung H.,
Takeshita J.,
Krueger G.G.,
Robertson A.D.,
Troxel A.B.,
Shin D.B.,
Van Voorhees A.S.,
Gelfand J.M.
Publication year - 2014
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.12745
Subject(s) - biostatistics , salt lake , epidemiology , medicine , family medicine , clinical epidemiology , library science , pathology , paleontology , structural basin , computer science , biology
Summary Background Treatment satisfaction among patients with moderate‐to‐severe psoriasis has not been studied and compared across treatments using a validated instrument. Objectives To assess patient‐reported satisfaction with systemic and phototherapy treatments for moderate‐to‐severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality‐of‐life measures. Methods This was a cross‐sectional study of 1182 patients with moderate‐to‐severe psoriasis in the Dermatology C linical E ffectiveness R esearch N etwork in the U . S . A . Patients receiving either topical therapies only; monotherapy with oral systemic therapies, biologics or narrowband ultraviolet B phototherapy; or combination therapy with biologics and methotrexate completed the T reatment S atisfaction Q uestionnaire for M edication version II. Results Median unadjusted overall satisfaction scores were highest for patients receiving biologic monotherapies, biologic–methotrexate combinations, or phototherapy (83·3); scores were lowest for those receiving topical therapies only or acitretin (66·7). In fully adjusted models, compared with patients receiving methotrexate monotherapy, those receiving adalimumab, etanercept, ustekinumab, phototherapy or adalimumab with methotrexate had significantly higher median overall satisfaction scores by 7·2–8·3 points, while those receiving topical therapies only had significantly lower overall satisfaction by 8·9 points. Adjusted convenience scores were lowest for patients receiving topical therapies only or infliximab. Modest but significant correlations were found between the overall satisfaction subscale and both the P soriasis A rea and S everity I ndex (ρ = −0·36, P < 0·001) and the D ermatology L ife Q uality I ndex (ρ = −0·47, P < 0·001). Conclusions Discernible differences were found in treatment satisfaction among therapies, particularly regarding treatment effectiveness and convenience. Further application of treatment satisfaction measures may inform treatment decisions and guideline development.